BidaskClub downgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a research report report published on Thursday, September 20th.
Several other analysts also recently commented on VYGR. ValuEngine upgraded Voyager Therapeutics from a buy rating to a strong-buy rating in a research note on Monday, July 2nd. Chardan Capital restated a hold rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, June 21st. BTIG Research restated a buy rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research note on Thursday, June 7th. Canaccord Genuity set a $35.00 price target on Voyager Therapeutics and gave the stock a buy rating in a research note on Wednesday, June 6th. Finally, Morgan Stanley restated an equal weight rating and issued a $27.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 10th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Voyager Therapeutics currently has a consensus rating of Buy and a consensus price target of $30.70.
Shares of Voyager Therapeutics stock traded up $0.43 during midday trading on Thursday, hitting $16.13. The company had a trading volume of 256,414 shares, compared to its average volume of 412,275. The company has a market capitalization of $613.69 million, a P/E ratio of -6.11 and a beta of 2.94. Voyager Therapeutics has a 52-week low of $11.54 and a 52-week high of $31.91.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. The company had revenue of $2.58 million during the quarter, compared to analysts’ expectations of $3.00 million. Research analysts predict that Voyager Therapeutics will post -3.12 earnings per share for the current fiscal year.
In other news, Director James A. Geraghty acquired 3,000 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was purchased at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the transaction, the director now directly owns 76,588 shares in the company, valued at approximately $1,485,041.32. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Glenn Pierce acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were purchased at an average price of $18.44 per share, with a total value of $92,200.00. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 11,000 shares of company stock worth $205,300. Insiders own 33.60% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. grew its position in Voyager Therapeutics by 37.5% in the second quarter. Oppenheimer & Co. Inc. now owns 22,000 shares of the company’s stock worth $430,000 after acquiring an additional 6,000 shares in the last quarter. Cim Investment Mangement Inc. purchased a new position in shares of Voyager Therapeutics during the second quarter valued at approximately $400,000. Trustees of Princeton University purchased a new position in shares of Voyager Therapeutics during the second quarter valued at approximately $3,979,000. BlackRock Inc. boosted its position in shares of Voyager Therapeutics by 18.8% during the first quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock valued at $27,020,000 after buying an additional 227,266 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Voyager Therapeutics during the first quarter valued at approximately $227,000. Institutional investors own 89.64% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.